Glutamate and Neuropsychiatric Disorders Current and Emerging Treatments

Dr. Zoran M. Pavlovic focuses his work on consulting pharmaceutical and biotech companies on clinical trial design, methodology, biomarkers and surrogate endpoints, patient-reported outcomes, and psychometric assessments, related to development of their drug candidates for treatment of major psychiatric and neurological disorders.

Dr. Pavlovic’s primary interests and expertise have centered on psychopharmacologic approaches to Chronic Stress, Major Depressive and Anxiety disorders, Substance Use Disorders, and Neurodegenerative Disorders.

Dr Pavlovic is the Editorial Board Member for Neuropsychiatric Disease and Treatment journal and Innovations in Clinical Neuroscience, and is the author of numerous scientific articles published in most eminent psychiatric, neuropsychiatric and psychopharmacological journals, such as the Official Journal of the American Neuropsychiatric Association, Official Journal of the European Psychiatric Association and the Official Journal of the Collegium Internationale Neuro-Psychopharmacologicum (CINP). Furthermore, Dr Pavlovic is the editor of the book “ Modulators of Glutamatergic Signaling as Potential Treatments for Neuropsychiatric Disorders ,” which was published in 2015 by Nova Science Publishers.